| pubmed-article:12966409 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12966409 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:12966409 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:12966409 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:12966409 | lifeskim:mentions | umls-concept:C1518321 | lld:lifeskim |
| pubmed-article:12966409 | lifeskim:mentions | umls-concept:C2698651 | lld:lifeskim |
| pubmed-article:12966409 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:12966409 | pubmed:dateCreated | 2003-9-10 | lld:pubmed |
| pubmed-article:12966409 | pubmed:abstractText | NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only. | lld:pubmed |
| pubmed-article:12966409 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966409 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966409 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966409 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12966409 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966409 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12966409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966409 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12966409 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12966409 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:12966409 | pubmed:author | pubmed-author:HutcheonA WAW | lld:pubmed |
| pubmed-article:12966409 | pubmed:author | pubmed-author:DelaneyEE | lld:pubmed |
| pubmed-article:12966409 | pubmed:author | pubmed-author:ParkinD EDE | lld:pubmed |
| pubmed-article:12966409 | pubmed:author | pubmed-author:CruickshankM... | lld:pubmed |
| pubmed-article:12966409 | pubmed:author | pubmed-author:PettyR DRD | lld:pubmed |
| pubmed-article:12966409 | pubmed:author | pubmed-author:McNallyO MOM | lld:pubmed |
| pubmed-article:12966409 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12966409 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:12966409 | pubmed:volume | 89 | lld:pubmed |
| pubmed-article:12966409 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12966409 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12966409 | pubmed:pagination | 966-7 | lld:pubmed |
| pubmed-article:12966409 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:meshHeading | pubmed-meshheading:12966409... | lld:pubmed |
| pubmed-article:12966409 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12966409 | pubmed:articleTitle | Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study. | lld:pubmed |
| pubmed-article:12966409 | pubmed:affiliation | Department of Gynaecology/Oncology, Ward 43, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB15 2ZN, Scotland. omcnally@doctors.org.uk | lld:pubmed |
| pubmed-article:12966409 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12966409 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12966409 | pubmed:publicationType | Comment | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12966409 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12966409 | lld:pubmed |
